DJ Drucker, MA Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
SE Inzucchi, RM Bergenstal, JB Buse et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
AJ Scheen, RP Radermecker Addition of incretin therapy to metformin in type 2 diabetes Lancet 375 2010 1410 1412
AJ Scheen GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris) 74 2013 515 522
AJ Scheen Exenatide once weekly in type 2 diabetes Lancet 372 2008 1197 1198
DR Owens, L Monnier, GB Bolli Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus Diabetes Metab 39 2013 485 496
JB Buse, J Rosenstock, G Sesti et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
DJ Drucker, JB Buse, K Taylor et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
T Blevins, J Pullman, J Malloy et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 1301 1310
C Wysham, T Blevins, R Arakaki et al. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 2014 10.2337/dc13-2760 published online May 30.
JB Buse, M Nauck, T Forst et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
RE Pratley, MA Nauck, AH Barnett et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 2014 289 297
KM Dungan, ST Povedano, T Forst et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 2014 published online July 11. http://dx.doi.org/10.1016/S0140-6736(14)60976-4
